ZymoGenetics, Inc. DN1BMC

DN1BMC Company Overview

ZymoGenetics, Inc. was a U.S.-based biotechnology company focused on the discovery, development, and commercialization of protein-based therapeutics for autoimmune diseases, inflammation, oncology, and infectious diseases. The company operated within the biotechnology and biopharmaceutical industries and became known for leveraging genomics and protein engineering capabilities to identify naturally occurring human proteins with therapeutic potential. Its principal revenue drivers historically included collaboration agreements, licensing arrangements, milestone payments, and limited commercial product revenue tied to partnered therapies.

The company was founded in 1981 in Seattle, Washington, and evolved from an early biotechnology research enterprise into a clinical-stage biopharmaceutical company with multiple partnered drug programs. ZymoGenetics developed a reputation for its expertise in protein therapeutics and recombinant biologics, particularly through work involving interferons, growth factors, and immune-regulating proteins. In 2010, Bristol-Myers Squibb acquired ZymoGenetics, Inc. in a transaction intended to strengthen Bristol-Myers Squibb’s biologics and immunology pipeline. Following the acquisition, ZymoGenetics ceased operating as an independent publicly traded company.